Top Data Analytics Companies (2,283)

Strong Revenue Growth: Revenue is rising year over year with multiple consecutive quarters of growth, capped by a strong recent quarter. Company disclosures attribute momentum to premium offerings and improved monetization.

Strong Market Position & Advantage: The platform is consistently ranked as the No. 2 U.S. real-estate portal and holds a sizable share of category visits. Its near-comprehensive MLS coverage underpins competitive scale and visibility.

Diversified Revenue Streams: Growth is supported by a shift toward higher-value products and expansion into seller, new-home, and rental segments. This mix broadening complements core lead-generation revenues.

Profitability: Profitability is trending upward in 2026, with management twice raising full-year adjusted EBIT guidance and North America’s EBIT margin improving to 8.6%. Strong demand, improved margins, lower EV losses, and higher operating efficiency are cited as drivers.

Strong Market Position & Advantage: Market position in the U.S. remains strong, with 2025 deliveries up 6% to about 2.9 million and market share rising to roughly 17.2%, alongside leadership in full-size pickups and full-size SUVs. Several brands posted record or decade-best results, and crossovers grew to more than 46% of sales by Q1 2026.

Healthy Cash Flow: Cash generation is viewed as robust, with executives indicating more than $10 billion of free cash flow per year on average over the last five years. Capital returns were reinforced by a higher dividend and a new $6 billion share repurchase authorization.

Strong Revenue Growth: Revenue increased 19% in 2025 and accelerated in 2026 with 22% year-over-year growth in Q1 and 27% in Q2, while first-half 2026 revenue rose 25% year over year. Management raised full-year 2026 guidance to $94–96M, implying roughly 22–24% growth.

Customer Loyalty & Retention: Net Dollar Retention reached 117% in Q1 2026, indicating expanding spend from existing accounts after churn. Core genomics customers rose to 537 as of March 31, 2026, with record new customer additions in 2025.

Market Expansion: Geographic momentum is evident with Q1 2026 analysis volume up 28% in the U.S. and 31% in APAC, and EMEA revenue up 30%. Platform usage set records (e.g., 108,000 analyses in Q1 and 115,000 in Q2), with liquid biopsy volumes growing sharply.

Strong Revenue Growth: Inc. 5000 recognitions cite 82% and 72% three-year growth, and investor disclosures note meaningful 2025 revenue scale, indicating sustained multi-year expansion. While precise YoY rates aren’t public, repeated list appearances and disclosed scale point to continued momentum.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in 2025 to support the next phase of growth, expansion, and platform investment. Additional financing and stated plans for strategic acquisitions further reinforce access to growth capital.

Market Expansion: Customer and data footprint expanded to 170M+ patient records across 200+ provider/payer organizations, with more than 2.25M value-based lives added in 2024. Management and media describe ambitions for further expansion via M&A and potential moves beyond the U.S.

Strong Revenue Growth: Financial statements indicate total revenue rose from $499.7M in 2024 to $737.5M in 2025, with clearing‑fee revenue increasing materially over the same period. Operating data into 2026 shows elevated activity levels, consistent with continued top‑line momentum.

Profitability: Net income increased from $70.2M in 2024 to $190.7M in 2025, and operating income shifted from losses in prior years to a positive result. This reflects improved earnings alongside higher clearing volumes.

Resilient & Sustainable Growth: Contracts cleared reached record levels in 2025 and continued to expand into 2026, while the securities‑lending program also grew in value and transactions. Multi‑year trends from 2020 to 2025 show options activity more than doubling, indicating durable expansion.

Profitability: Adjusted EBITDA and margins expanded, with Q2 2026 EBITDA up 30% year over year and margin improving to 37%, alongside higher net income. This pattern indicates operating leverage as earnings outpace the top line.

Strong Revenue Growth: Revenue rose 7% in 2025 and accelerated to 11% year over year in Q2 2026, with multiple sequential quarters showing improving trends. The recent trajectory points to faster growth rather than a flat profile.

Healthy Cash Flow: Free cash flow is guided to grow at more than 30% for 2026 and was later raised to the high-40% range, while Q2 2026 generated $57.4M in operating cash. Debt reduction in 1H 2026, including repayment of $205M in convertibles, further supports balance-sheet strength.

Market Expansion: The company reports a larger operating footprint—supporting around 150 million vehicles and approximately 14 million annual service events—and has expanded via strategic moves such as the Urgently acquisition. New and renewed programs with major automotive and insurance brands further indicate broader market reach.

Strong Market Position & Advantage: Industry recognition such as Frost & Sullivan’s North American Company of the Year honors portrays a commanding position in digitalized roadside assistance. Claims of extensive OEM integrations and deep insurer penetration reinforce an entrenched competitive stance.

Innovation-Driven Growth: Continued investment in software-enabled dispatch platforms, automation, and connected-vehicle tools is emphasized as central to the strategy. Rapid uptake of Crash Response and other digital workflows points to technology-enabled scaling.

Strong Revenue Growth: Company disclosures indicate annual recurring revenue increased in 2023, with higher‑margin recurring services expanding even faster, pointing to healthy momentum in the recurring mix.

Product Line Growth: Product expansion is evident with the 2025 launch of Vendavo AI and subsequent 2026 AI/ML feature releases, including a High‑Tech Revenue Management solution.

Market Expansion: An agreement in 2026 to acquire Model N’s High‑Tech business unit broadens capabilities into channel data management and semiconductor/high‑tech markets. New enterprise wins such as Dassault Aviation suggest a widening footprint.

Strong Revenue Growth: Recent results indicate FY2026 revenue rose 19% year over year to roughly $2.02B, with Q1 FY2027 revenue up 16% and ARR up 17%. This points to steady double‑digit expansion across both total and recurring revenue.

Customer Loyalty & Retention: Dollar-based net retention is reported around 110–111%, and ARR growth has tracked slightly ahead of revenue growth. These signals suggest existing customers are expanding usage alongside new logo additions.

Healthy Cash Flow: Company materials highlight strong free cash flow alongside growth, including substantial FY2026 free cash flow and robust margins in recent quarters. The business has also returned capital via notable share repurchases.

Strong Revenue Growth: Revenue grew 26% year over year in FY2024. ARR increased 30% in 2023 after crossing the $100M threshold in 2022.

Profitability: Operations remained profitable and cash‑flow positive in FY2024 while the organization expanded to just under 600 employees.

Investor Backing & Capital Strength: A July 2024 majority investment led by Vista Equity Partners (with TCV and KKR) valued the company at about $1.2B. This reflects substantial external capital support for continued expansion.

Investor Backing & Capital Strength: Funding includes a $70M Series C in May 2025 with participation from firms such as a16z, Sequoia, Redpoint, and Snowflake Ventures. This indicates substantial investor confidence and available capital to scale.

Market Expansion: Customer reach is described as 2,000+ organizations, up from 1,500+ teams in May 2025, and the company highlights success with enterprises of 2,500+ employees (e.g., Toast, Cruise, Rivian). This suggests movement beyond smaller data teams into larger enterprise adoption.

Product Line Growth: The platform added embedded analytics in 2025 and is centering on AI-powered analytics with its Notebook Agent, while also broadening BI surface area via the Hashboard acquisition. These additions expand addressable use cases from internal notebooks to embedded and agentic analytics.

Strategic Partnerships: Partnerships with major platforms and retailers are expanding distribution and activity. Feedback suggests Uber and Giant Eagle joined in 2026 and a multi‑year 7‑Eleven deal was announced, while relationships with Walmart, Instacart and DoorDash underpin third‑party publisher redemption revenue up 27% year over year in Q2 2026.

Market Expansion: Network usage is scaling across publishers and channels. Feedback suggests Q2 2026 redeemers rose 21% to 20.9M, third‑party publisher redemptions increased 27% year over year, and H1 2026 total redemptions climbed from 163.3M to 179.4M.

Strong Market Position & Advantage: Positioning reflects a leading role in U.S. digital promotions with privileged retailer access. Feedback suggests Walmart exclusivity, a network reaching 200M+ consumers, and 900+ clients representing 3,100+ CPG brands provide a defensible competitive footing.

Strong Revenue Growth: Revenue has scaled materially, with ARR approaching the $400M mark and leadership targeting expansion toward $1B, alongside earlier signals such as 42% YoY ARR growth and very high renewal/net expansion. Feedback suggests recent indications of ~$300–350M revenue and expanding customer/end‑user coverage reinforce continued momentum.

Investor Backing & Capital Strength: A majority investment by Vista Equity Partners at an approximately $3B valuation signals strong capital support and confidence in the company’s scaling prospects. Feedback suggests this backing, including associated financing, enables continued product and geographic expansion.

Strong Market Position & Advantage: Repeated recognition as a Leader in Gartner’s DEX Magic Quadrant (2024–2026) and Forrester’s EUEM Wave points to sustained category leadership. Large‑scale enterprise adoption (e.g., 1,500+ customers and 25M+ employees served) further entrenches competitive positioning.

Strong Revenue Growth: Available disclosures indicate revenue grew at a triple‑digit rate year over year in early 2026 and was later described as roughly $200M after multiple years of doubling. These signals point to rapid scaling beyond a purely funding‑led story.

Investor Backing & Capital Strength: Back‑to‑back late‑stage rounds in 2026, including a nine‑figure Series D followed quickly by a nine‑figure Series E with a stepped‑up valuation, suggest deep capital access and investor conviction. The rapid valuation increase provides additional financial flexibility for expansion.

Strategic Partnerships: Announcements in 2026 with organizations such as Atlantic Health and Priority Health indicate expanding distribution channels beyond direct employer sales. These relationships broaden market reach and embed the offering within health systems and plans.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Strong Revenue Growth: Revenue is consistently climbing across 2025 and into 2026, with management increasing full‑year guidance after stronger‑than‑expected quarters. Momentum is led by U.S. Financial Services and Emerging Verticals, with multiple quarters of high single‑ to double‑digit organic growth noted.

Profitability: Net income and adjusted earnings expanded alongside revenue, and adjusted EBITDA also increased. This points to improving operating leverage as growth scales across key segments.

Diversified Revenue Streams: Multiple business lines—including credit, fraud/identity, marketing, and international operations—are contributing to results. Expansion such as taking majority ownership in the Mexico bureau and broad-based U.S. segment strength reduce reliance on any single product or geography.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Revenue Growth: ARR is reported as more than tripled in 2025, with annual recurring subscription and service revenue increasing by over 220%. Growth is attributed to new and expanding relationships with private equity sponsors and their portfolio companies.

Market Expansion: Office openings and relocations across Chicago, Dallas, New York, and Toronto, plus expanded sponsor footprint and portfolio reach, indicate widening geographic and commercial coverage. The company cites doubling sponsor partnerships and reach into a network representing about $400B AUM.

Strong Hiring & Retention: Headcount is estimated to have risen sharply over 2023–2026, and multiple executive appointments (e.g., EVPs for Finance & Corporate Development and for Technology & Operations) were made to support scaling. Added locations and planned team growth in hubs like Chicago and New York further signal ongoing talent expansion.

Strong Revenue Growth: Consolidated revenue has increased across recent years, with additional year-over-year gains extending into early 2026. This pattern indicates ongoing top-line expansion even as quarterly and annual growth rates vary.

Profitability: Operating income reached new highs in 2025 and continued to rise in subsequent quarters. This points to improving operating leverage alongside revenue growth.

Product Line Growth: Businesses such as Morningstar Credit, PitchBook, Retirement, and the Direct Platform are cited as key growth engines, with Credit standing out. This breadth of product contributions supports expansion beyond a single offering.